---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006086"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:17:23.019903+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Q3 revenue falls 13% to $22M; net loss widens to $4.8M

## Summary
- Revenue $22.0M, down 13.4% YoY from $25.4M; gross margin stable at 58.1%.
- GAAP net loss $4.8M (($0.11)/diluted share) vs $1.2M loss a year ago; included $1.2M non-cash pension settlement charge.
- Adjusted EBITDA $1.3M (6.0% margin) vs $2.2M (8.9%) prior year; nine-month adjusted EBITDA $4.2M vs $10.9M.
- Operations used $0.8M cash in Q3 vs $4.4M generated last year; revolving credit facility constrained by net leverage ratio.
- CEO cites challenging market; expects $1M quarterly cost savings from additional actions starting Q4; new products gaining adoption.

## SEC filing metadata
- accession: 0001171843-24-006086
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184324006086/0001171843-24-006086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184324006086/f8k_110724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006086
- JSON: https://secwatch.observer/filing/0001171843-24-006086.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.